The importance of adequately managing multidrug-resistant (MDR) and extensively drug-
resistant (XDR) tuberculosis (TB) cases for TB control and elimination are underlined in the …

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) continue
to be challenging at both the patient and programme level. The World Health Organization …

BACKGROUND: For the first time in almost 50 years, there are new drugs available for the
treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate …

The current treatment for drug-resistant tuberculosis (TB) is long, complex, and associated
with severe and life-threatening side effects and poor outcomes. For the first time in nearly …

Bedaquiline, a recently approved drug for the treatment of multidrug-resistant tuberculosis
(MDR-TB), is recommended for a duration of 24 weeks. There are scarce data on patients …

Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-
resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and …

Bedaquiline, a diarylquinoline, improved cure rates when added to a multidrug-resistant
tuberculosis (MDR-TB) treatment regimen in a previous placebo-controlled, phase 2 trial …

Background The emergence of drug resistance is a major threat to global tuberculosis (TB)
care and control. The World Health Organization (WHO) estimates that up to half a million …

Abstract The World Health Organization (WHO) recommends countries introduce new anti-
TB drugs in the treatment of multidrug-resistant tuberculosis. The aim of the study is to …

SETTING: The World Health Organization recommended two new drugs, bedaquiline (BDQ)
and delamanid (DLM), for the treatment of multidrug-resistant tuberculosis (MDR-TB) in …